Digi International Introduces Digi IX30 Cellular Router Solution for Harsh Environments and Industry 4.0 Adoption
Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today unveiled Digi IX30, an industrial-hardened cellular router solution for harsh environments. Digi IX30 provides edge intelligence in a ruggedized, industry-leading design for the highest levels of reliability and flexibility. Coupled with Digi Remote Manager ®, Digi IX30 is an all-in-one solution for applications including distribution and automation, as well as remote machine and sensor monitoring in industries such as oil and gas production, water utilities, smart cities, and outdoor signage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005021/en/
Digi's new IX30 cellular router solution for harsh environments and industry 4.0 adoption provides edge intelligence in a ruggedized, industry-leading design for the highest levels of reliability and flexibility. Coupled with Digi Remote Manager®, Digi IX30 is an all-in-one solution for applications including distribution and automation, as well as remote machine and sensor monitoring in industries such as oil and gas production, water utilities, smart cities, and outdoor signage. (Photo: Business Wire)
Digi IX30 is powered by Digi Remote Manager (Digi RM) and the Digi Accelerated Linux operating system (DAL OS). Digi RM is the command center of an intelligent network, enabling companies to efficiently configure, deploy, monitor, and manage tens of thousands of mission-critical devices and assets from a single desktop, tablet or smartphone. DAL OS, along with Digi RM, enables programmability for edge intelligence applications, interoperability for legacy serial devices/protocols, and MQTT Sparkplug B. These capabilities deliver critical connectivity between devices and sensors in the Industry 4.0 ecosystem, allowing users to experience high levels of security, control, and performance.
Ready for Public or Private Cellular Networks in ONE Solution
Digi IX30 delivers fast performance for public, private, and hybrid network deployments that support both licensed spectrum and CBRS Band 48 to enable migration between multiple networks in a single SKU. A future variant of Digi IX30 will include Anterix Band 8 along with Anterix Active certification to offer public and Anterix private cellular network support.
Battle Tested for Harsh Environments
Digi has designed its entire industrial (IX) product family to meet high-performance requirements in harsh environments with wide temperature ranges. Its Class 1, Division 2 (C1D2) and ATEX certifications makes it suitable for environments where potentially explosive gases, vapors, dust, or fibers may be present, and its DIN rail mounting design enables easy installation in field containers and cabinets.
Highest Density of I/O Options, Edge Intelligence and Complete Features for Global Deployments
Digi IX30 has the highest number of analog and digital I/O and serial ports along with rich protocol support and offers versatile integration options to manage a large of number of legacy systems from a single piece of equipment.
Digi IX30 was designed with dual Ethernet ports and GNSS, as well as support for remote sensors with four analog and four digital inputs and outputs. Leveraging its new Python programming implementation that provides interoperability with legacy serial devices/protocols, the Digi IX30 solution brings greater reliability, simplicity, and security to edge computing.
For customers who deploy and manage systems globally, Digi’s IX line provides a single SKU for high-volume global deployment, which simplifies inventory and reduces the costs of global distribution, deployment, and management.
“Digi IX30 – the newest member of our next-generation IX family of devices – builds on our widely successful legacy of industrial cellular routers,” said Sayeed Quazi, Sr. Principal Product Manager at Digi. “The ruggedized IX30, with additional compute for edge applications and additional analog and digital I/O, reduces the points of failure by eliminating the need for additional equipment. Its faster performance and LTE speeds deliver greater value through a complete, cost-effective IoT solution and significantly reduces OPEX in the most challenging deployment.”
The Digi IX30 industrial router is available immediately through global distributors.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005021/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom